Table 3.

Diagnostic test statistics of the study cohort showing the accuracy and missed cancer rates for each phi threshold as a triage test pre-MRI and biopsy. PSAd thresholds are shown as a comparator though this metric is not usually available before an mpMRI. Detection rates for cancer are shown using definitions of ≥ Grade Group 2 (GG2) or ≥ Cambridge Prognostic Group 3 [CPG3]. (*percentage out of 258 cancers detected, ** percentage out of 176 cancers detected)

	≥ GG2 cancer detection					≥ CPG3 cancer detection
	Threshold	Sensitivity	Specificity	NPV	% cancers missed*	Sensitivity	Specificity	NPV	% cancers missed**
phi	20	0.99	0.10	0.90	1.1	1.00	0.08	1.00	0
	25	0.96	0.25	0.87	4.2	0.99	0.22	0.99	0.05
	30	0.92	0.40	0.85	7.7	0.95	0.35	0.94	1.0
	35	0.87	0.55	0.83	12.8	0.93	0.49	0.93	7.3
PSAd	0.10	0.93	0.31	0.82	7.3	0.97	0.28	0.95	2.8
	0.15	0.81	0.57	0.77	18.6	0.90	0.53	0.92	9.6
	0.20	0.69	0.77	0.73	31.3	0.80	0.72	0.88	20.0